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Abstract
Novel data streams (NDS), such as web search data or social media updates, hold
promise for enhancing the capabilities of public health surveillance. In this paper, we
outline a conceptual framework for integrating NDS into current public health
surveillance. Our approach focuses on two key questions: What are the opportunities
for using NDS and what are the minimal tests of validity and utility that must be
applied when using NDS? Identifying these opportunities will necessitate the
involvement of public health authorities and an appreciation of the diversity of
objectives and scales across agencies at different levels (local, state, national,
international). We present the case that clearly articulating surveillance objectives and
systematically evaluating NDS and comparing the performance of NDS to existing
surveillance data and alternative NDS data is critical and has not sufficiently been
addressed in many applications of NDS currently in the literature.
Keywords: disease surveillance; novel data streams; digital surveillance
1 What are novel data streams?
We define NDS as those data streams whose content is initiated directly by the user (pa-
tient) themselves. This would exclude data sources such as electronic health records, dis-
ease registries, vital statistics, electronic lab reporting, emergency department visits, am-
bulance call data, school absenteeism, prescription pharmacy sales, serology, amongst
others. Although ready access to aggregated information from these excluded sources is
novel in many health settings, our focus here is on those streams which are both directly
initiated by the user and also not alreadymaintained by public health departments or other
health professionals. Despite this more narrow definition our suggestions for improving
NDS surveillance may also be applicable to more established surveillance systems, partic-
ipatory systems (e.g., Flu Near You, influenzaNet) [, ], and new data streams aggregated
from established systems, such as Biosense . and ISDS DiSTRIBuTE network [, ].
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While much of the recent focus on using NDS for disease surveillance has centered on
Internet search queries [, ] and Twitter posts [, ], there aremanyNDS outside of these
two sources. Our aim therefore is to provide a general framework for enhancing and devel-
oping NDS surveillance systems, which applies to more than just search data and Tweets.
At aminimum, our definition ofNDSwould include Internet search data and socialmedia,
such as Google searches, Google Plus, Facebook, and Twitter posts, as well as Wikipedia
access logs [, ], restaurant reservation and review logs [, ], non-prescription phar-
macy sales [, ], news source scraping [], and prediction markets [].
2 How does NDS integrate into the surveillance ecosystem?
UsingNDS for surveillance or in supporting public health decisionmaking necessitates an
understanding of the complex link between the time-varying public health problems (i.e.,
disease incidence) and the time-varying NDS signal. As illustrated in Figure , this link
is modified by user behavior (i.e., propensity to search, what terms are chosen to search,
etc.), user demographics, external forces on user behavior (i.e., changing disease severity,
changing press coverage, etc.), and finally by public health interventions, which by design
aim to modify the public health problem creating feedback loops on the link to NDS. As
a result, developing NDS-based surveillance systems presents a number of challenges,
many of which are comparable to those faced by systems comprised of more established
data sources such as physician visits or laboratory test results.
NDS could add value to existing surveillance in several ways. NDS can increase the time-
liness of surveillance information, improve temporal or spatial resolution of surveillance,
add surveillance to places with no existing systems, improve dissemination of data, mea-
sure unanticipated outcomes of interest (i.e. a syndrome associated with a new pathogen
that is not currently under surveillance in an established system), measure aspects of a
transmission/disease process not captured by traditional surveillance (i.e. behavior, per-
ception), and increase the population size under surveillance.
The most studied example of the potential benefits and unique challenges associated
with NDS comes fromGoogle Flu Trends. In , Google developed an algorithmwhich
translates search queries into an estimate of the number of individuals with influenza-like
illness that visit primary healthcare providers []. The original goal of Google Flu Trends
(GFT) was to provide accessible data on influenza-like illness in order to reduce reporting
delays, increase the spatial resolution of data, and provide information on countries out-
side the United States of America []. GFT has added value to existing surveillance for
Figure 1 The link between public health
problems and NDS is modified by user behavior
(i.e., propensity to search, what terms are chosen
to search, etc.), user demographics, external
forces on user behavior (i.e., changing disease
severity, changing press coverage, etc.), and
finally by public health interventions, which by
design aim to modify the public health problem
creating feedback loops on the link to NDS.
Althouse et al. EPJ Data Science  (2015) 4:17 Page 3 of 8
influenza. However, although there has been some benefit both to academic researchers
and public health practitioners, GFT has also received criticism [, ].
Much of the recent criticism of GFT seems to stem from two issues: the first is the effect
of changing user behavior during anomalous events [, ] and the second is whether
real-time, nowcasting of influenza using GFT adds value to the existing systems avail-
able to public health authorities. The first criticism, changing behavior during anomalous
events, is an issue for both existing systems and proposed systems based on NDS. The
key difference is that existing systems may be both better understood and easier to vali-
date in real-time. While such criticisms may not undermine the case for use of NDS, they
do emphasize that the validation of any NDS approach is an ongoing process, and even
a perfectly validated system in one period or location may become uncalibrated as be-
haviors change. It is therefore not meaningful to say that a particular NDS system is or is
not informative; that statement must be qualified in space and time. Moreover, the fact
that decalibration to “gold standard” systems cannot be detected immediately but only in
retrospect is another reason why NDS can only supplement and never fully replace such
systems. The second criticism, the need for nowcasting, may depend on the user’s access
to different data sources. For public health authorities with access to high-resolution data
on reported cases of influenza, simple autoregressive models can be used to nowcast with
high accuracy []. However, access to these high resolution data-sets varies by public
health level (local, state, federal, and international) as well as by user group: researchers,
public health authorities, and the private sector. As a result, the utility of GFT varies by
user, but for those without access to high-resolution data, it remains an important source
of information.
Since the release of GFT, similar NDS-based systems have been developed to extend
surveillance to places where resource or other constraints limit the availability of direct
clinical or laboratory surveillance data and improve the timeliness of detection and fore-
casting of disease incidence. For example, NDS have facilitated expansion of dengue and
influenza surveillance to countries without infrastructure capable of real time surveil-
lance [, , , ]. This has also been done in the context of hospitalizations in Texas [],
mental illness, psychological manifestations of physical morbidities [, ], and search
queries from clinical decision support sites, such as UpToDate []. In these cases, al-
though NDS-based systems are being asked to estimate data that is actually being col-
lected, those data are not available quickly enough for use in public health decision mak-
ing.
As stated earlier, in some cases NDS can be used to assess behavior - something that re-
mains a challenge for traditional case-based surveillance. Although this is a challenge for
translating NDS signals into estimates of disease incidence, it presents a unique oppor-
tunity to study health seeking behavior. For example, NDS has facilitated an exploration
of population-level changes in health-related behaviors following changes in tobacco re-
lated policy [, ] or after unpredictable events such as celebrity deaths or cancer diag-
noses [, ]. NDS can help us understand andmonitor health-related behavior, but little
recent work has focused on this area. How does vaccination sentiment respond to changes
in disease prevalence? How is health-seeking behavior discussed in social networks? Does
that information dissemination manifest in action? Answering these questions accurately
may require integration of Twitter, Facebook, Wikipedia access logs, web searches or web
search logs, hospitalization records, and EMR with existing measures of behavior such
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as the Behavioral Risk Factor Surveillance System. As a result, it is critically important
to understand the user’s intent; for example, what are the behavioral, biological, and/or
epidemiological underpinnings of information-seeking online? A Google or Wikipedia
search for the keyword “ulcer”, for instance, is likely a response to having symptoms of
an ulcer while a search for “h pylori” is more likely a response to something more specific,
such as a lab confirmed test for an ulcer-causative agent. Similarly, posting a Tweet about a
“healthy recipe” is likely a different action than searching for a “healthy recipe”; where the
former is an act of broadcasting information, while the latter is an act of searching for in-
formation. This suggests that large-scale experiments combiningNDS could explore these
behaviors.
Therefore, in order to address the challenges associated with NDS-based surveillance
and properly integrate NDS into existing systems, we advocate for a three-step system:
() Quantitatively define the surveillance objective(s); () build the surveillance systems
and model(s) by adding data (existing and novel) in until there is no additional improve-
ment inmodel performance to achieve stated objectives, assessed by () performing rigor-
ous validation and testing. These steps are comparable to those prescribed for evaluating
more established systems [].
3 How dowe ensure the robustness of NDS surveillance systems?
NDS, by their very definition, do not have a long track record of use. As a result, rigor-
ous standards for validating NDS and systems constructed using NDS must be adopted.
These validation procedures should include both best practices in machine learning and
also best practices from surveillance systemdesign such as the proportion of persons iden-
tified that are true positives for the disease under surveillance []. Building on previous
work [], we have systematically evaluated the existing published NDS surveillance pa-
pers using the following criteria: was validation used and if so what type, are the data open
and if not why not, and is the code open source. While we understand that it’s not always
possible, due to privacy concerns and data use agreements, to make data open access, it’s
essential that the community be able to externally validate methods and NDS. Therefore,
a component of validation must be the use of data that is publicly available (or at least
available to researchers) for training and testing of NDS. Of  papers identified, only 
(%) performed any validation, only one [] stated that the source code was available, and
while some used publicly available data, no papers publicly shared the data used in their
analyses. (see Table  and Table S in Additional file ).
While the lack of validation is troubling, there is a deeper issue: it may be the case that
many existing standards for validation are inadequate for use on disease surveillance sys-
tems using NDS [, ]. For example, there are well-documented cases of failure when
the training set does not contain important dynamics of the system [–]. For that rea-
son we advocate for model development by repeated training and testing on subsets of the
data and that a final, validation set be held back entirely during model construction [].
This final validation set should be used only once, at the conclusion of the study. Ideally,
Table 1 The use of open source code and validation across papers using NDS for surveillance
Validation No validation
Open source code 1/66 (1.50%) 0/66 (0%)
No open source code 26/66 (39.4%) 39/66 (59.1%)
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this final set will be completely blind to the developer. Lastly, after these development
and validation steps, models should be openly evaluated prospectively to further support
their validity. Put simply, this approach could be summarized as internal validation, exter-
nal validation, and continued prospective evaluation.While these steps help to ensure the
validity of models, it may be that given the volatile nature of disease processes and human
behavior (non-linear and non-stationary dynamics), it may be technically impossible to
design robust surveillance systems using proxy data and regression models alone.
Validation must also be conducted by other researchers. First, transparency of methods
and reproducibility of forecasts is essential to both the scientific process and in examining
the utility of models/NDS. Second, new methods or NDS must demonstrate improve-
ments upon existing methods or data sources. Performance can be over-stated by com-
paring performance of NDS systems with trivial instances of traditional models. Clear
definition of appropriate baseline models and their definition is critical to assessing the
improvement of new models utilizing novel streams. Without open access to data and
code, these crucial steps are not possible. Ideally, manuscripts would report, in detail, the
methods employed, provide open-source code implementing those methods, and make
the data used to generate the prediction available. Despite legitimate concerns about pri-
vacy, data use agreements between agencies, and the often substantial effort required to
gather data, we must work towards ensuring our scientific publications are replicable and
useful for evaluating the next generation of surveillance tools.
Validation can also be conducted by complementary studies. For example, researchers
could conduct studies on how users interact with NDS sources, such as Google or Twitter.
These detailed studies would provide valuable information on potential biases and suggest
mechanisms for improving the robustness of surveillance systems constructed from these
NDS. The need for these focused studies again highlights the utility of collaboration of
private sector companies, such as Google and Twitter, with researchers and public health
practitioners. Recent efforts by Google and Twitter to better engage with the research
community represents an important first step.
4 What is the future of NDS surveillance?
NDS should provide robust, long-term surveillance solutions. Even after EMR are at the
fingertips of public health decision-makers and researchers, NDS will provide a snapshot
of activity, which is unrelated to themedical encounter. Therefore, a critical first stepwhen
evaluating NDS for surveillance is determining what problems are likely to be short term
andwhat problems are likely to be longer term. Again, clearly defined quantitative surveil-
lance goals must be the most important components of NDS-driven systems.
A second important distinction is that surveillance needs, potential benefits, and general
utility vary by country, region, and locality. For example, many state and local health agen-
cies in the U.S. already have access to high-resolution, near real-time data for infectious
diseases. In this case, local utility may be limited to understanding behavioral responses.
These data are also useful, however, for validating these systemsmore generally. In regions
where less data is available, the utility of models may be high but comprehensive evalua-
tion may not be possible. Finally, both Internet and website (or app) penetration vary by
geographic region.
Clearly, NDS cannot replace physician and laboratory data, though it can be used to
augment the surveillance coming out of systems collecting that type of data. Furthermore,
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the need for model validation highlights the often-overlooked importance of maintaining
traditional/existing systems in the existingNDS literature.Without these systems, it would
be impossible to validate and update NDS-enabled systems.
As a community of researchers and public health decision makers, we must decide on
how to proceed. Specifically, we must ensure stability and robustness of these NDS-based
systems. Pure research is important, but if our goal is to design systems to support public
health decisions, they must achieve a higher level of stability. Peer review of systems must
carefully evaluate validation relative to established surveillance systems. This of course
gives rise to the open question of who should be responsible for funding and maintain-
ing these new systems. The future success of these efforts hinges on building and main-
taining collaborations between private-sector, public health agencies, and academics. Fi-
nally, while the field has been critical of Google and GFT, it is because we are able to
criticize: No other NDS-based system had continuously provided public health predic-
tions for as long as GFT, many NDS surveillance systems had not been as carefully eval-
uated [, –], and fewer still had been implemented prospectively. Despite the recent
cessation of GFT, Google provided a living system for NDS surveillance. Next generation
surveillance systems using NDS hold great promise for improving the health of our global
society. Realizing their potential will require more rigorous standards of validation and
improved collaboration between researchers in academia, the private sector, and public
health.
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